Pulnovo Medical anuncia los resultados del ensayo PADN-HF-PH en el Congreso ESC 2026

Data ReadoutpositivePADN-HF-PHPositive

AI Analysis

Summary

Pulnovo Medical announced positive results from the PADN-HF-PH trial at ESC 2026, demonstrating a 51% reduction in clinical worsening risk in 264 PH-LHD patients, with simultaneous publication in The New England Journal of Medicine.

Clinical Trial Data

Primary Endpoint

Met

Patients

264

Outcome Details

51% reduction in risk of clinical worsening in 264 patients with PH-LHD

Importance:7/10

Sentiment:

0.80

clinical trial resultsESC CongressNEJM publicationpulmonary hypertensionheart disease

Related Companies

$SHWZ $MDCE

Read the original article

Published by PR Newswire Pharma on September 3, 2026 7:42 PM

Read Original